Technologies

Pharmaceuticals & Vitamin D : Pain

Technologies

Long-Lasting, Non-Narcotic Protein for Treatment of Acute or Chronic Pain

UW–Madison researchers have developed a chimeric protein that may be used to treat acute or chronic pain. The protein consists of a peptide ligand that specifically targets neurons involved in pain processing and a botulinum toxin light chain protein that blocks the release of neurotransmitters that cause pain. The therapeutic could be delivered through the spine to result in long-lasting, stable and reversible regulation of pain.
P130093US02

Benzodiazepine Derivatives with Reduced Side Effects for Treatment of Neuropathic Pain

Researchers at the University of Wisconsin-Milwaukee have developed new benzodiazepine derivatives useful in the treatment of neuropathic pain with reduced sedative and ataxic effects. GABA is the major inhibitory neurotransmitter in the central nervous system. Non-selective benzodiazepine drugs, such as valium, act by enhancing the inhibitory effects of GABA at GABAA receptors in the CNS. These drugs broadly target GABAA receptors containing a1, a2, a3, or a5 subunits.

Recently, it was discovered that the various effects of non-selective benzodiazepines are specifically mediated through certain a subunit-containing GABAA receptor populations in the brain. a1-containing GABAA receptors control sedation, whereas the anti-anxiety and anti-pain activity works mainly through a2 and a3 receptors. a5 receptors play critical roles in learning and memory consolidation.

The inventors of this technology have produced GABAA receptor agonists specific for a2 and a3 receptors. Because the compounds do not affect a1 receptors, they have significant neuropathic pain protection without sedative and ataxic effects. In addition, the compounds are anxiolytic and anti-convulsant. The inventors are carrying out pre-clinical testing of these compounds by conducting in vitro studies and animal studies in rats, mice and monkeys. These compounds were found to have significant neuropathic pain protection in mice and rats without causing sedation, muscle relaxation or ataxic effect.
T09021US02

Using Conjugated Linoleic Acid to Inhibit Cyclooxygenase-2 and Reduce Inflammation

UW-Madison researchers have developed a COX inhibitor that does not cause the ulceration associated with COX-1 inhibition or cardiovascular problems associated with COX-2 inhibition. Conjugated linoleic acid (CLA) relieves pain and inflammation by inhibiting COX-2 without negatively affecting the digestive tract or cardiovascular system. Until now, CLA has not been recognized as a COX-2 inhibitor.
P99048US